Antimicrobial resistance (AMR) represents an overlooked pandemic. Recent data estimate 4·95 million deaths associated with bacterial AMR globally in 2019. This has directed global efforts towards research and development of new generations of antimicrobials that includes non-antibiotic therapeutics that could be used as monotherapy or in combination with traditional antibiotics to restore their activity. In this talk I will present our recent progress in developing novel combination therapies that hold potential as antibiotic resistance breakers against drug resistant bacteria and potentiate antibiotic activity against highly tolerant biofilms.